Opthea announces publication of Phase 2b trial results of OPT-302

Opthea announced that the Phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D "trap" agent administered in combination with Lucentis for the treatment of wet age-related macular degeneration, have been published online in Ophthalmology, the journal of the American Academy of Ophthalmology. The prospective, randomized, controlled Phase 2b trial of 366 treatment-naive patients with wet AMD, conducted at 109 clinical sites across the United States, Europe and Israel, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the pre-specified primary efficacy endpoint of a statistically superior gain in visual acuity at 24 weeks, compared to ranibizumab alone. In addition, secondary outcomes were positive for the OPT-302 combination therapy including more participants with gains in vision of 10 or more letters, improved anatomy of reduction in swelling and vascular leakage, with a favorable safety profile.